Form 8-K

8-K — Zeo ScientifiX, Inc.

Accession: 0001829126-26-005695

Filed: 2026-05-27

Period: 2026-05-27

CIK: 0001557376

SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — zeoscientifix_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (zeoscientifix_ex99-1.htm)

GRAPHIC (ex99-1_001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: zeoscientifix_8k.htm · Sequence: 1

false

0001557376

2026-05-27

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of report (Date of earliest event reported): May 27, 2026

ZEO SCIENTIFIX, INC.

(Exact name of registrant as specified in its charter)

Nevada

000-55008

47-4180540

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

3321 College Avenue, Suite 246

Davie, Florida

33314

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s telephone number, including area code: (888) 963-7881

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each Class

Trading Symbol

Name of each exchange on which registered

None

N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

As used in this Current Report on Form 8-K (this

“Report”), and unless otherwise indicated, the terms “the Company,” “ZEO,” “we,”

“us” and “our” refer to Zeo ScientifiX, Inc.

Item 8.01 Other Events.

On May 27, 2026, ZEO issued a press release announcing

the formal launch of its Physician-Led Patient Masterclass program designed to help physicians mobilize their patient population and provide

critical education to current and potential patients about regenerative medicine.

A copy of the press release is included as Exhibit

99.1 to this Report.

Item 9.01 Financial Statements and Exhibits.

(d)

Exhibits

Exhibit No.

Description

99.1

Press Release, dated May 27, 2026

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: May 27, 2026

ZEO SCIENTIFIX, INC.

By:

/s/ Ian T. Bothwell

Ian T. Bothwell

Chief Executive Officer and Chief Financial Officer

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: zeoscientifix_ex99-1.htm · Sequence: 2

Exhibit 99.1

ZEO

ScientifiX Launches Physician-Led Patient Masterclass Program

Following Grassroots Demand in the Southeast

After training more than 600 physicians in under a year, the biologics research and products company now turns its focus to assisting physicians in educating their patients on the science of regenerative medicine.

DAVIE, FLORIDA, May 27, 2026 -- ZEO ScientifiX, Inc. (OTCQB: ZEOX) (“ZEO ScientifiX” or the “Company”), a biologics research and products company dedicated to educating physicians on the science of regenerative medicine, today announced the formal launch of its Physician-Led Patient Masterclass program. The initiative formalizes a model that emerged organically in Vero Beach, Florida, and marks the Company’s next strategic move: helping physicians mobilize their patient population and provide critical education to current and potential patients about regenerative medicine, something physicians have indicated has been in large demand.

In the past year alone, ZEO ScientifiX trained more than 600 physicians across the Southeast in the clinical application of regenerative therapies, including the utilization of stem cells for the three indications recently permitted under Florida law: pain management, wound care, and orthopedics. That network was built quietly and deliberately. What happened in Vero Beach made clear that it was time to activate it.

A Room Full of Questions

The program did not begin as a corporate initiative. Dr. Alita Sikora, a physician based in Vero Beach, who has attended prior ZEO ScientifiX’s physician focused Masterclasses, decided to organize a local patient education event on her own. The objective was simple: inform patients in the community about regenerative medicine and potential ways regenerative medicine may be a viable health treatment option. The promotion was minimal. The response was not.

When ZEO ScientifiX Director of Growth Strategy Karlista Maroney attended one of the sessions, she found the room packed wall to wall. Chairs had run out. Patients came to understand their options for pain, wound care, and orthopedic conditions and to ask the questions a standard clinical appointment rarely leaves room for.

“I walked into that room expecting a small gathering and found it packed wall to wall. They had run out of chairs. What Dr. Sikora built, without a campaign or a playbook, was proof that this conversation was already overdue. Patients want to understand their options. They want to know what is in the products being used in their care, where they come from, and whether it is right for them. That room told me exactly where we needed to go next. Our job is to set our physicians up to have that conversation at-scale. When patients are comfortable with their physician’s knowledge of the subject and see their focus on safety and science they can make better decisions regarding their heath treatment options and ultimately the types of products they want to explore. Physicians need to be more proactive with their patients to help stimulate their practices. Demand for regenerative medicine is growing, and we intend to foster that every way possible. That is the model.”

– Karlista Maroney, Director of Growth Strategy, ZEO ScientifiX

From Physician Network to Patient Movement

The Masterclass program formalizes the structure Dr. Sikora demonstrated: a physician-hosted event designed to walk patients through the science, the appropriate use cases, and considerations of determining whether regenerative therapy is appropriate for their health plan. ZEO ScientifiX equips participating physicians with the educational framework and supporting materials. The clinical conversation remains entirely in the physician’s hands.

The program also addresses a growing patient safety concern. As regenerative medicine expands in visibility, variability in product quality and sourcing has followed. ZEO ScientifiX sees physician-led education as a mechanism to help patients understand what questions to ask and what standards to hold their providers accountable to, regardless of where they ultimately seek care.

“We built this physician network to drive clinical excellence and real practice growth. The Masterclass program is the logical extension of that work. An educated patient is a better patient. When physicians can have these conversations with their communities in depth, outcomes improve and trust is built. That is what sustainable growth looks like in this space. We are proud of what Dr. Sikora demonstrated and we are ready to scale it.”

– Sean Vega-Stanton, General Manager, ZEO ScientifiX

About the Program

The ZEO ScientifiX Physician-Led Patient Masterclass is open to physician partners across the Company’s Florida network. Events are designed to be hosted locally, tailored to the community, and grounded in clinical education. Topics include the biological basis of regenerative therapies, appropriate use cases permittable under Florida law, patient selection criteria, and product sourcing and quality standards.

Physicians interested in hosting a Patient Masterclass event may contact ZEO ScientifiX directly.

About ZEO ScientifiX (OTCQB: ZEOX)

ZEO ScientifiX is a regenerative medicine biologics research and products company dedicated to advancing patient outcomes through physician-run clinics. ZEO supplies cutting-edge biologics and regenerative therapies, partnering with clinicians to drive clinical excellence and sustainable practice growth.

Forward-Looking Statements

Certain statements contained in this press release should be considered forward-looking statements within the meaning of the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. Actual results could vary dramatically. ZEO has no intention and specifically disclaims any duty to update the information in this press release.

Media Contact

ZEO ScientifiX, Inc.

Karlista Maroney

Director of Growth Strategy

ir@zeoscientifix.com

# # #

GRAPHIC

Filename: ex99-1_001.jpg · Sequence: 6

Binary file (50316 bytes)

Download ex99-1_001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

May 27, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

May 27, 2026

Entity File Number

000-55008

Entity Registrant Name

ZEO SCIENTIFIX, INC.

Entity Central Index Key

0001557376

Entity Tax Identification Number

47-4180540

Entity Incorporation, State or Country Code

Entity Address, Address Line One

3321 College Avenue

Entity Address, Address Line Two

Suite 246

Entity Address, City or Town

Davie

Entity Address, State or Province

Entity Address, Postal Zip Code

33314

City Area Code

(888)

Local Phone Number

963-7881

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration